Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.38 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.34 |
| ▸ | BCL6 | P41182 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25210492 | 0.88 | HDAC6 (0.39) | HDAC6FPR2HDAC1HDAC4KDM4E | |
| SCHEMBL16688836 | 0.88 | HDAC1 (0.43) | HDAC6FPR2HDAC1HDAC2HDAC4 | |
| SCHEMBL23885335 | 0.86 | HDAC6 (0.38) | HDAC6FPR2HDAC1HDAC4KDM4E | |
| SCHEMBL23885578 | 0.84 | HDAC6 (0.50) | HDAC6FPR2HDAC1HDAC2HDAC4 | |
| SCHEMBL25540462 | 0.83 | HDAC6 (0.39) | HDAC6FPR2HDAC1HDAC4KDM4E | |
| SCHEMBL23885169 | 0.80 | HDAC1 (0.41) | HDAC6HDAC1HDAC2NT5EHDAC4 | |
| SCHEMBL30254754 | 0.80 | CNR1 (0.43) | HDAC1HDAC2KDM4EALDH1A1MAPKAPK2 | |
| SCHEMBL25235315 | 0.80 | DOT1L (0.42) | HDAC6KDM4EALDH1A1 | |
| SCHEMBL16688860 | 0.78 | HDAC6 (0.37) | HDAC6FPR2 | |
| SCHEMBL19208246 | 0.75 | FPR2 (0.45) | HDAC6FPR2KDM4EALDH1A1BCL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | C5, C9, C1QBP | HDAC6 2412/4885FPR2 593/4885HDAC1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.